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ABSTRACT:
As multiple stakeholders rush to address the opioid epidemic, federal policy definitively asserts
Medication Assisted Treatment (MAT) constitutes the most effective solution and should be
expanded to all persons with Opioid Use Disorder (OUD). This article traces how federal policy
strategically collapsed different categories of persons who misuse opioids – those with
physiological dependence along with persons with addiction – and why discounting relevant
differences contradicts current research. Delving into controversial presumptions weaving
addiction science, healthy policy, and law, this article explains the intersection between addiction
and crime, personal choice and neurobiology, and analyzes how current evidence in fact
demonstrates critical flaws underlying the premise of MAT. Media reports, litigation, and case
law exemplify the tragic outcomes of MAT’s failures when Opioid Treatment Providers offer
insufficient care to address patients’ underlying addiction. As a result, patients merely obtain an
additional substance that fuels active polysubstance abuse, resulting in patient impairment
undermining individual recovery and posing a threat to public safety and welfare.
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INTRODUCTION
In 2017, media began reporting on the case Commonwealth v. Eldred, in which Julie
Eldred pled guilty to larceny for stealing jewelry to finance her habit of abusing fentanyl. 1 As a
condition of her probation, the court ordered Eldred to remain “drug free” but permitted her to
utilize Suboxone, a partial opioid agonist, as part of medication assisted treatment (MAT) for her
Opioid Use Disorder (OUD).2 Several days into outpatient treatment, Eldred relapsed by
abusing fentanyl.3 Eldred violated the probation condition to remain drug free, and failed the
court’s drug toxicology screening. 4 Based on her probation violation, the court ordered Eldred
into an inpatient facility. 5 Eldred was held in jail for several days until her attorney could find
her a space in an inpatient treatment facility. 6 Eldred’s attorney and media reports portrayed the
case as punishing people for their addiction, asserted Eldred’s relapse constituted an action she
could not control, and called the court’s action “cruel, arbitrary, and unfair.” 7 Eldred represents
multiple assumptions underlying the current opioid crisis from how we define substance abuse
and addiction; why substance abuse intersects with crime and involves public safety; whether
persons with a substance use disorder (SUD) have any control over their actions; and whether the
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Deborah Becker, Court to Rule on Whether Relapse by and Addicted Opioid User Should Be a Crime, NPR (Oct.
26, 2017), https://www.npr.org/sections/health-shots/2017/10/26/559541332/court-to-rule-on-whether-relapse-byan-addicted-opioid-user-should-be-a-crime; Maura Ewing, ‘The Court System Shouldn’t Interrupt the Treatment
Process,’ THE ATLANTIC (Dec. 16, 2017), https://www.theatlantic.com/politics/archive/2017/12/opioidsmassachusetts-supreme-court/548480/.
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See Brief for the Probationer on a Reported Question and On Appeal from Finding a Probation Violation,
Commonwealth v. Eldred, No. SJC 12279, (Mass. June 2017) (hereinafter “Eldred Brief”); Brief of the
Commonwealth of Massachusetts on a Reported Question and On Appeal from Finding a Probation Violation,
Commonwealth v. Eldred, No. SJC 12279, (Mass. Aug. 2017) (hereinafter “Commonwealth Brief”).
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Id.; Alanna Durkin, If Addiction is a Disease, Should Relapse Mean Jail Time?, U.S. NEWS & WORLD REPORT
(Oct. 22, 2017), https://www.usnews.com/news/news/articles/2017-10-02/if-addiction-is-a-disease-should-relapsemean-jail-time.
7
Eldred Brief, supra note 2, at 6; Becker, supra note 1; Ewing, supra note 1; Maria Kramer, SJC to Weigh if Courts
Can Force Sobriety on Drug Users, BOSTON GLOBE (Sept. 24, 2017),
https://www.bostonglobe.com/metro/2017/09/24/sjc-weigh-courts-can-force-sobriety-drugusers/6a9dm1MSqufTD3I6bbuFoJ/story.html.
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federal policy presumption that expanding access to MAT constitutes an effective and optimal
solution for persons with OUD.8
In Part I, this article will summarize arguments presented in Commonwealth v. Eldred,
which mirror many of the ongoing health policy debates relating to defining SUD, and will
describe the intersection between substance abuse, public safety, and crime. Part II will outline
federal policy set forth by the National Institute on Drug Abuse (NIDA) that describes SUD as a
brain disease that “hijacks” 9 normal neurobiological functioning, impairs decision-making, and
impedes control.10 According to NIDA and the Substance Abuse and Mental Health
Administration (SAMHSA), SUD is similar to other chronic lifelong diseases, in that it requires
treatment using highly effective medication in place of punishment, and relapse constitutes an
expected outcome. 11 Despite the dominant model classifying SUD as a chronic brain disease,
not all health professionals and scientists agree. Part II of this article will also provide an
overview of conflicting viewpoints demonstrating flaws in the current brain disease model,
articulate why SUD is unlike other diseases, explain how a narrow neurobiological focus
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See Office of the Assistant Secretary for Planning and Evaluation, Opioid Abuse In The U.S. And HHS Actions To
Address Opioid-Drug Related Overdoses And Deaths - Executive Summary, DEPT. HEALTH AND HUMAN SERVICES
(Mar. 26, 2015), https://aspe.hhs.gov/pdf-document/opioid-abuse-us-and-hhs-actions-address-opioid-drug-relatedoverdoses-and-deaths-executive-summary.Drug; Effective Treatment for Opioid Addiction, NATIONAL INSTITUTE ON
DRUG ABUSE, (Nov. 2016), https://www.drugabuse.gov/publications/effective-treatments-opioidaddiction/effective-treatments-opioid-addiction (hereinafter “Effective Treatment for Opioid Addiction”);
Medications to Treat Opioid Use Disorder, NATIONAL INSTITUTE ON DRUG ABUSE, (Mar. 2018),
https://www.drugabuse.gov/publications/research-reports/medications-to-treat-opioid-addiction/overview
(hereinafter “Medications to Treat Opioid Use Disorder”); FDA Takes New Steps To Advance The Development Of
Innovative Products For Treating Opioid Use Disorder, FOOD AND DRUG ADMINISTRATION (Apr. 20, 2018),
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm605248.html.
9
Alan Leshner, Addiction is a Brain Disease and Why it Matters, 278 (5335) SCIENCE 45 (1997).
10
Id.; Drug Facts: Treatment Approaches for Drug Addiction, NATIONAL INSTITUTE ON DRUG ABUSE (Jan. 2018),
https://www.drugabuse.gov/publications/drugfacts/treatment-approaches-drug-addiction (hereinafter “Drug Facts”);
Drugs, Brains, and Behavior: The Science of Addiction, NATIONAL INSTITUTE ON DRUG ABUSE (Jul. 2014),
https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/preface (hereinafter “Drugs,
Brain, and Behavior”).
11
Id.
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undermines strategies to prevent and treat SUD, and why the concept of choice and personal
agency constitutes a vital part of recovery.
Part III describes the evidence behind MAT, outlines three FDA approved medications
used in MAT, and provides an overview of laws governing their use in medical care. Part IV
provides critical analysis of the metrics health professionals use to determine MAT efficacy,
discusses the impact of MAT on quality of life and potential recovery, and why current evidence
does not support expanding MAT to all persons with OUD. Finally, Part V will consider the
implications of expanding MAT by examining massive shortcomings relating to regulation of
Opioid Treatment Providers (OTPs), discrepancies in treatment quality and regulatory
compliance, and how case law compels a fresh examination of the current treatment paradigm.
I. THE IMPACT OF DRUG ABUSE ON PUBLIC SAFETY AND WELFARE
A. Commonwealth v. Eldred
Julie Eldred began experimenting with OxyContin in high school, when occasional use to
ease social anxiety expanded to abusing heroin and years of struggling with addiction. 12
Eldred’s larceny charge was also not her first: she had been arrested previously on another
larceny charge, during which she also violated her probation by abusing opioids. 13 The present
case, Commonwealth v. Eldred, demonstrates the pervasive struggle with addiction, relapse, and
the intersection of SUD and crime.14 Persons with SUD are not punished for their status of
having an addiction, but instead for specific criminal acts that impact public welfare and safety.
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Ewing, supra note 1.
Id.
14
See also Eric Westervelt, To Save Opioid Addicts, This Experimental Court is Ditching the Delays, NPR (Oct. 5,
2017), https://www.npr.org/sections/health-shots/2017/10/05/553830794/to-save-opioid-addicts-this-experimentalcourt-is-ditching-the-delays, (discussing crimes such as petty larceny as a means to obtain money to purchase drugs
and a new model of diversion into rapid treatment).
13
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Eldred raised controversial questions and attracted national attention. Multiple interested
parties filed amicus briefs on behalf of each party attempting to distill the answers to murky
questions in the realm of penalties, addiction, and treatment. If SUD constitutes a brain disease
and relapse is inevitable, then may the court impose a probation condition for Eldred to remain
drug free (in this case, permitting prescribed Suboxone)? Is her compulsion to continue to abuse
illicit drugs so overwhelming that she cannot resist? If she violated her probation by abusing
fentanyl, may the court find she violated the conditions of her probation? Eldred raises questions
not only of the parameters of criminal responsibility, but also fundamental questions of choice,
agency, and the extent of compulsion. The resolution of this case, and how the court views
relapse (even when receiving treatment) and a condition to remain drug free will have significant
consequences for the ability to sanction criminal acts committed by persons with SUD to protect
public safety. It also raises broader questions of what constitutes effective treatment for persons
with SUD in a manner that advances compassion and aids in successful recovery.
Eldred’s Arguments
In appealing the probation violation, counsel for Eldred asserted a variety of claims
premised on the brain disease model of addiction. Adopting former NIDA Director Alan
Leshner’s terminology, Eldred argued drug abuse hijacked her brain, initiating a series of
modifications to brain structure and learning that impaired her ability to control her actions. 15
Marked by an overwhelming desire to continue abusing drugs, Eldred asserted she experienced
intolerable distress if she stopped using. 16 This prompted a vicious cycle of drug seeking that
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Eldred Brief, supra note 2, at 1, 8-9, 11-12, 27.
Id. at 8-9.
5

overpowered her and undermined her ability to control her impulse to use fentanyl despite the
threat of negative consequences. 17
Eldred also used NIDA’s metaphor that SUD is like other diseases, such as diabetes or
hypertension, because these diseases have both physiological and behavioral aspects involved in
their progression and management. 18 Based on this comparison, a person with hypertension who
experiences high blood pressure also experiences a relapse of a disease, but we view the state of
high blood pressure as an involuntary medical condition, an inherent symptom of the disease,
and the patient cannot control the disease symptoms. Just as we would not punish a person with
hypertension who experiences high blood pressure, Eldred argued relapsing and abusing fentanyl
constitutes a symptom of SUD – a symptom that she cannot control and the court cannot
penalize.19 Eldred further asserted that finding a relapse violated her probation constituted an
ineffective and counterproductive threat that merely attempted to shame Eldred for a medical
disorder that eliminated her capacity to exert any free will over her actions. 20 According to
Eldred, that amounted to criminalizing her addiction under a different name, which is “cruel,
arbitrary, . . . unfair,” unconstitutional, and “shocks the conscience.” 21
Eldred’s articulation of the brain disease model garnered the support of multiple parties
including the Massachusetts Medical Society and the American Civil Liberties Union of
Massachusetts, both submitting amicus briefs echoing Eldred’s arguments. 22 The Massachusetts
Medical Society further issued a public statement on the case, urging the court to adopt Eldred’s
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Id. at 1, 8-9.
Id. at 11-12, 14.
19
Id. at 11-12, 14, 33, 37.
20
Id. at 32-33.
21
Id. at 6, 37.
22
Amicus Curiae Brief of the American Civil Liberties Union of Massachusetts et al., Commonwealth v. Eldred, No.
SJC 12279, (Mass. Sept. 2017); Amicus Curiae Brief of the Massachusetts Medical Society et al., Commonwealth v.
Eldred, No. SJC 12279, (Mass. Sept. 2017).
18
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arguments proffered in the appeal. The Massachusetts Medical Society asserted the medical
community operates with a “clear scientific consensus” that SUD is a chronic condition, relapse
is an “almost inevitable” symptom of the disease, and an order to refrain from abusing drugs
during treatment as a condition of probation “condemns patients for living with a chronic
disease.”23 The American Civil Liberties Union of Massachusetts similarly declared enforcing a
drug free condition of probation is “dangerous and unjust.” 24
The Commonwealth’s Arguments
The Commonwealth’s arguments supported the court’s finding that Eldred’s decision to
abuse fentanyl violated her probation and described pertinent nuances between SUD, choice, and
punishable offenses. 25 As a preliminary note, the Commonwealth clarified that Eldred’s
involvement in the criminal justice system arose from her admission of guilt to a larceny
charge.26 In lieu of incarcerating Eldred for larceny, the court offered probation and treatment
with a condition to refrain from abusing illicit substances. According to the Commonwealth,
drug free conditions on probation enforced through periodic drug testing are designed to promote
compliance and further public safety: in Eldred’s case, treatment compliance to assist in her
recovery and reduce her potential of future involvement in the criminal justice system. 27
The Commonwealth noted that the brain disease model of addiction is not only
controversial and contested by scientists and health professionals, but also fails to support the
principle that persons with SUD lose their free will and are completely unable to exert control
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Id.; MMS Releases Statement Regarding Amicus Brief in Commonwealth v. Eldred, MASSACHUSETTS MEDICAL
SOCIETY (Sept.19, 2017), http://www.massmed.org/News-and-Publications/MMS-News-Releases/MMS-ReleasesStatement-Regarding-Amicus-Brief-in-Commonwealth-v--Julie-Eldred/#.WzJPxKdKg2w.
24
Id.
25
The Commonwealth asserted although people with SUD may face difficulties with addiction, they do not lose
their free will to make alternate choices toward recovery. Further, courts do not punish people for the state of
having an addiction, but instead for specific crimes that impact public safety and welfare.
26
Commonwealth Brief, supra note 2, at 2-3.
27
Id. at 2, 15-16.
7

over their actions. 28 The Commonwealth rejected Eldred’s assertion that SUD is similar to other
chronic diseases because persons with SUD can and do respond positively to contingency
management plans (giving patients tangible reinforcement for positive behaviors and sanctioning
negative behaviors), which would have no impact on a disease such as cancer or Alzheimer’s
disease.29 Even if drug abuse induces neurobiological changes, the Commonwealth clarified it is
unlike other brain diseases, such as Alzheimer’s disease, where the person loses genuine capacity
to control the disease by acts of will. 30 The distinguishing feature of SUD compared to another
diseases, such as Alzheimer’s disease or cancer, lies in Eldred’s capacity to exert control over
her actions.
Thus, although Eldred’s decision-making may be impaired, she is not a powerless
automaton.31 Imposing a condition to remain drug free as part of probation can motivate
engagement in treatment because successful recovery relies on the person’s individual
commitment to refrain from drug abuse.32 Indeed, according to the Commonwealth, no court has
found that drug use by a person with SUD is involuntary, because this would undermine the
court’s ability to assign culpability for drug-related crimes.33 Most importantly, the court’s
finding of a probation violation was not punishing Eldred for her mere status as a person with
addiction, but for a specific act – a willful violation of probation corresponding to her criminal
penalty for larceny. 34
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Id. at 5-6, 12.
Id. at 7.
30
Id. at 11.
31
Id. at 37-38.
32
Id. at 11, 32, 34.
33
Id. at 36.
34
Id. at 21, 34.
29
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B. The Intersection of Drug Abuse and Crime
Some media and legal scholarship decries a failed war on drugs, portraying drug abuse
and addiction as senseless incarceration of persons merely based on their addiction. 35 Yet as the
Commonwealth noted, many cases, including Eldred’s, are not punishing persons for having an
addiction but involve a specific crime that directly impacts the welfare of society, which may be
motivated or influenced by the individual’s drug abuse. Illicit drugs are costly to both the
individual and society: they decrease individual and societal productivity, increase medical costs,
contribute to mental distress, and can result in death. 36 Crimes connected to drug use include
offenses such as distributing the drug to others, crimes related to attempting to obtain money to
purchase drugs (such as larceny), offenses associated with a lifestyle of associating with illicit
markets, and public safety (driving under the influence, neglect of dependents, and interpersonal
violence).37 Political scientist James Q. Wilson aptly argued the notion that drug abuse is a
victimless crime “is not only absurd by dangerous” because we “all have a stake in ensuring each
of us displays minimal levels of dignity, responsibility and empathy.” 38 This translates to an

See Marc Kupanski, It’s Time to Kick Our Addiction to the War on Drugs, STAT NEWS (Apr. 25, 2017), available
at https://www.statnews.com/2017/04/25/opioids-war-on-drugs-harm-reduction/ (asserting punishment for crimes
relating to possession and sale of drugs do not deter such crimes, and advocates for supervised drug consumption
sites); Don Stemen, Beyond the War on Drugs, 11 HARVARD LAW & POLICY REVIEW 375, 375-377 (2017) (calling
the war on drugs an “utter failure” that ravaged and further marginalized impoverished communities); David
Lebowitz, Proper Subjects for Medical Treatment? Addiction, Prison-Based Drug Treatment and the Eighth
Amendment, 14 DEPAUL JOURNAL OF HEALTH C ARE LAW 271, 273 (2012) (asserting it is “uncontroversial that
many Americans are in prison because they are addicted to drugs”).
36
Barbara Andraka-Christou, Improving Drug Courts through Medication-Assisted Treatment for Addiction, 23
VIRGINIA JOURNAL OF SOCIAL POLICY & LAW 179-181 (2016); Facing Addiction in America: The Surgeon
General’s Report on Alcohol, Drugs, and Health, Office of the Surgeon General, DEPT. HEALTH AND HUMAN
SERVICES (2016) at 1-12, available at https://addiction.surgeongeneral.gov/ (discussing costs and consequences of
substance abuse) (hereinafter “Surgeon General’s Report).
37
Principles of Drug Abuse Treatment for Criminal Justice Populations - A Research-Based Guide, NATIONAL
INSTITUTE ON DRUG ABUSE (Apr. 2014), https://www.drugabuse.gov/publications/principles-drug-abuse-treatmentcriminal-justice-populations/introduction (hereinafter “Principles of Drug Abuse Treatment for Criminal Justice
Populations”).
38
James Q. Wilson, Against the Legalization of Drugs, COMMENTARY M AGAZINE (Feb. 1, 1990), available at
https://www.commentarymagazine.com/articles/against-the-legalization-of-drugs/.
35
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ethical responsibility to offer care and compassion to persons with addiction while also
maintaining the public safety and welfare.
NIDA acknowledges the connection between drug abuse and crime is well known, and
the Federal Bureau of Investigation using Uniform Crime Reports provides statistics for the
intersection of drug abuse and specific categories of crimes. 39 To illustrate: 30% of state
prisoners reported they committed property theft for the reason of obtaining money to purchase
illicit drugs, and approximately 37% of state prisoners committed the crime while under the
influence of a drug, which may impair decision-making, decrease impulse control, and diminish
sound judgment.40 In the context of persons with opioid addiction specifically, the media has
covered a variety of criminal allegations, such as diversion and sale of prescribed opioid
medications (including medications intended for MAT),41 fatal motor vehicle accidents caused
by a driver impairment by persons receiving MAT, 42 and child neglect or abuse by persons
struggling with OUD.43
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Principles of Drug Abuse Treatment for Criminal Justice Populations, supra note 37; Drug Use and Crime Facts,
Bureau of Justice Statistics, U.S. DEPARTMENT OF JUSTICE, https://www.bjs.gov/content/dcf/duc.cfm.
40
Id.; Mirko Bargaric & Sandeep Gopalan, A Sober Assessment of the Link Between Substance Abuse and Crime –
Eliminating Drug and Alcohol Use from the Sentencing Calculus, 56 SANTA CLARA LAW REVIEW 243, 243-302
(2016).
41
Deborah Sontag, At Clinics, Tumultuous Lives and Turbulent Care, NEW YORK TIMES (Nov. 17, 2013),
https://www.nytimes.com/2013/11/.../at-clinics-tumultuous-lives-and-turbulent-care.html; Laura Ungar, Rogue
Doctors Exploit Loopholes to Let a Powerful Drug ‘Devastate a Community,’ COURIER JOURNAL (June 8, 2017),
https://www.courier-journal.com/story/news/investigations/2017/06/08/rogue-doctors-hands-medicine-designedtreat-addiction-turns-into-new-habit/98522426/; Marty Schladen, Cash-only Suboxone Clinics Fuel Fears of New
‘Pill-Mills’, THE COLUMBUS DISPATCH (Oct. 8, 2017), http://www.dispatch.com/news/20171008/cash-onlysuboxone-clinics-fuel-fears-of-new-pill-mills/1.
42
Andrew Kruger, Judge Allows Punitive Damages in Lawsuit Against Brainerd Methadone Clinic, DULUTH NEWS
TRIBUNE (Sept. 24, 2014), http://www.duluthnewstribune.com/news/3846521-judge-allows-punitive-damageslawsuit-against-brainerd-methadone-clinic; Ella Nilsen, First of Four Parts: A Life Changer: Effects of Methadone
Treatment Extend Beyond Users, THE KEENE SENTINEL (Nov. 7, 2014),
http://www.sentinelsource.com/news/special_reports/methadone/first-of-four-parts-a-life-changer-effects-ofmethadone/article_386944f2-c506-5974-ab01-14a7ab629502.html; Ella Nilsen, Fourth of Four Parts: A Stage Set
for Disaster, THE KEENE SENTINEL (Nov. 11, 2014), available at
http://www.sentinelsource.com/news/special_reports/methadone/methadone_day_4/fourth-of-four-parts-a-stage-setfor-disaster/article_9da5f51c-a255-5d9b-aec8-85d2aadd6a17.html.
43
Michael Levenson, Concern Mounts on Opioid Crisis’ Toll on Children, BOSTON GLOBE (Oct. 17, 2015),
https://www.bostonglobe.com/metro/2015/10/17/concern-mounting-about-opioid-crisis-toll10

Criminal law scholars Mirko Bagaric and Sandeep Gopalan acknowledge that many
persons with an addiction likely do not consciously choose a life of despair and may not weigh
the impact of their actions (such as theft, impaired driving, or child neglect). 44 People born into a
life of social disadvantage, poverty, or unspeakable emotional and physical trauma expertly
chronicled by physician Dr. Gabor Mate may be more likely to engage in drug abuse and suffer
from addiction.45 But Bagaric and Gopalan assert that even if negative life events predispose
certain possibilities, this does not foreclose individual choice of alternatives. 46 Importantly, the
damage caused by these crimes, and the consequences of drug abuse, reverberate significant
harm to surrounding persons in society which is not diminished simply because the person
committing the crime was impaired by the influence of drugs. 47
Legal scholar and former prosecutor Susan Broderick notes the intersection of crime and
addiction requires policymakers to consider both public health and public safety considerations
when determining appropriate policy measures relating to SUD. 48 The law, according to
Broderick, serves as leverage to hold people accountable for their actions. 49 When addiction

children/bbKXGdk4iKry1l6vAcb4hO/story.html; Whitney Wetzel, Surge in Child Abuse and Neglect Cases, WCHS
EYEWITNESS NEWS, http://wchstv.com/features/eyewitness-news-i-team-investigations/surge-in-child-abuse-neglectcases-as-opioid-epidemic-worsens; see also Troy Quast et al., Opioid Prescription Rates and Child Removals, 37(1)
HEALTH AFFAIRS (2017) https://doi.org/10.1377/hlthaff.2017.1023 (finding a correlation between increased opioid
prescribing and an increase in child removal by the Florida Department of Child and Family Services due to neglect
or abuse.)
44
Bargaric & Gopalan, supra note 40, at 244, 264.
45
See generally Gabor Mate, In the Realm of Hungry Ghosts (2008). Mate chronicles his patients’ life histories and
stories of addiction, asserting “drug addiction is a matter of brain chemistry gone askew under the influence of a
substance and, as we will see, even before the use of mind-altering substances begins…people’s brain physiology
doesn’t develop separately from their life events and emotions.” Mate at 30. Mate describes neglect and severe
physical and sexual abuse of his patients, many of who are intractable polysubstance abusers, homeless,
unemployed, and are cycles in and out of the criminal justice system. Many began using drugs as “emotional
anesthetic” and “antidote” to the pain and trauma of their lives. Mate at 33.
46
Bargaric & Gopalan, supra note 40, at 288-289. See generally Cart Hart, High Price: A Neuroscientist’s Journal
of Self-Discovery (2013) (describing lack of options for persons in economically and socially disadvantaged areas
and rational choice to abuse drugs).
47
Bargaric & Gopalan, supra note 40, at 244.
48
See Susan Broderick, The Law and the Criminal Justice System, RECOVERY RESEARCH INSTITUTE (June 26,
2017), https://www.recoveryanswers.org/blog/recovery-answers-from-an-criminal-justice-public-policy-expert/.
49
Id.
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intersects with crime, this may take the form of several options, such as drug courts that refer
offenders with true addiction to appropriate and effective treatment. 50 This raises pertinent
questions of how to determine whether a person needs treatment, and whether certain types of
treatment promoted by NIDA and the Office of National Drug Control Policy, such as MAT, are
supported by adequate evidence. 51 Finally, not all drug-related offenders require treatment, and
for offenders who may not have an addiction, providing an alternate model that uses the lever of
the law to encourage responsible behavioral choices should be explored. 52 As a model, Hawaii’s
Opportunity Probation with Enforcement (HOPE) program employs swift, certain, and fair
sanctions to motivate behavioral outcomes. 53 The HOPE program has demonstrated measurable
statistical success and has been implemented in forty jurisdictions across eight states showing
reduction in crime.54
II. CRITICAL ANALYSIS OF THE BRAIN DISEASE MODEL
Considering solutions to address substance abuse and finding answers to the controversial
questions raised in Commonwealth v. Eldred requires examining the state of substance abuse in
the United States and how federal policy defines and characterizes persons with SUD. This

50

See Treatment Courts Work, NATIONAL ASSOCIATION OF DRUG COURT PROFESSIONALS,
https://www.nadcp.org/treatment-courts-work/; Paul Larkin, Swift, Certain and Fair Punishment: 24/7 Sobriety and
HOPE: Creative Approaches to Alcohol and Illicit-Drug Using Offenders, 105 JOURNAL OF CRIMINAL LAW &
CRIMINOLOGY 39, 79-80 (2015) (discussing how participation in drug treatment can substantially reduce drug use
and crime).
51
Michael Botticelli, Memorandum: Changing Federal Terminology Regarding Substance Use and Substance Use
Disorders, OFFICE OF NATIONAL DRUG CONTROL POLICY (Jan. 9, 2017),
https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Memo%20%20Changing%20Federal%20Terminology%20Regrading%20Substance%20Use%20and%20Substance%20Use%2
0Disorders.pdf (hereinafter “ONDCP Memo”).
52
Larkin, supra note 50, at 75.
53
Id. Larkin provides an overview of the shortcomings used in traditional substance abuse testing, outlines the
model for probation with frequent substance testing back by the possibility of flash incarceration for noncompliance.
Larkin at 66-67, 71-72. Statistics from HOPE are promising, demonstrating the program had an 80% decrease in
positive drug tests among participants, participants were 52% less likely to be arrested for a new crime, and 72%
less likely to use drugs. Larkin at 73. See also Beau Kilmer et al., Back in the National Spotlight: An Assessment of
Recent Changes in Drug Use and Drug Policies in the United States, BROOKINGS INSTITUTE (Aug. 2016) at 16,
https://www.brookings.edu/wp-content/uploads/2016/07/Kilmer-United-States-final-2.pdf.
54
Kilmer, supra note 53, at 16.
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section will provide an outline of the dominant brain disease model of addiction in federal policy
set forth by NIDA that characterizes SUD as a chronic and relapsing medical disorder marked by
fundamental changes in neurological functioning. It will next provide critical analysis of the
dominant brain disease model based on evidence showing why SUD is unlike a chronic disease,
how neurological changes do not preclude choice, and discuss the importance of recognizing
individual agency in recovery. Lastly, this section will explain the significance of recognizing
distinct populations of persons with OUD ranging from physiological dependence to addiction.
A. The Impact of Drug Addiction and the Brain Disease Analogy
SUD related to opioids affects a significant portion of the population in the United States:
in 2016, 2.1 million persons had an opioid use disorder.55 U.S. annual spending on drugs has
remained relatively stable, but the compositions of drugs of abuse has shifted, where more
persons are abusing opioids (both prescription opioids and heroin) and marijuana. 56 The Centers
for Disease Control and Prevention has called opioid abuse a fast moving epidemic, and in 2017
the Secretary of Health and Human Services declared the opioid crisis a public health
emergency.57 These trends closely follow political and prescribing changes: as more physicians
began writing more prescriptions for opioids, rates of overdose and death also skyrocketed. 58
From 1999 to 2013, the rate of overdose from OxyContin increased five-fold.59
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Medications to Treat Opioid Use Disorder, supra note 8, at 3.
See Kilmer, supra note 53, at 4-9.
57
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The “Hijacked Brain”: Neurological Changes and Choice
NIDA defines drug addiction as “compulsive, or uncontrollable, drug seeking use despite
harmful consequences and changes in the brain, which can be long lasting.” 60 People may
initially abuse drugs for a variety of reasons, classified broadly as seeking euphoria or relief from
dysphoria,61 including as a remedy to address “psychic pain, existential maladies, emptiness, lack
of purpose, or isolation.”62 Although initial drug use begins as a voluntary action, as a person
continues using the drug, it creates neurological changes in how the brain learns, remembers, and
functions.63 Use of the drugs releases dopamine in the brain, which reinforces the pleasurable
effects of the drug as a reward with each subsequent use.64 Repetition of these patterns induces
neuroplastic changes in the brain, strengthening the association between the drug and euphoria,
reinforcing the drug as a habit, and bolstering the expectation of pleasure. 65 Positron emission
tomography (PET) scans show progressive changes in areas of the brain such as the prefrontal
cortex that affect judgment, self-control, and decision-making and gradual loss of gray matter in
the brain.66
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These neurological changes, according to NIDA Director Nora Volkow, impair neural
scaffolding that enable self-control, undermining the person’s ability to resist abusing drugs.67
Psychiatrist, Colm Connolly and colleagues demonstrated duration of substance abuse correlates
with decreases in gray matter in the brain in areas associated with executive functioning,
judgment, decision-making and reward processing. 68 The longer a person abuses substances, the
greater the negative impact to both neurological structure and functioning. 69 Persons with SUD
experience both altered sensitivity to negative reinforcers (consequences of their addiction, such
as economic loss, criminal involvement, loss of child custody etc.) and also attribute excessive
salience to the drug itself. 70 Behaviors relating to drug seeking and consumption become main
motivational drivers at the expense of other activities and responsibilities present in daily life.71
These adaptations are what compromises a person’s ability to choose, resulting in
compulsive drug use, which invokes Leshner’s concept of the “hijacked brain.” 72 According to
the American Society of Addiction Medicine, after continued drug abuse, a person develops a
tolerance to the drug and “needs” the drug not to experience euphoria, but to avoid feeling the
distress of withdrawal and associated dysphoria. 73 The American Society of Addiction Medicine
asserts, without continuing to abuse the drug of choice, the individual feels “flat, lifeless, and
depressed.”74
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A Diseased Brain: Addiction is Similar to Other Chronic and Relapsing Diseases
Federal policy maintains substance abuse should be treated as a medical condition and is
similar to other chronic diseases such as heart disease or diabetes. 75 Indeed, NIDA compares
temporal neurological modifications for persons with addiction visually represented by PET
scans (a “diseased brain”) to images of a patient with heart disease (a “diseased heart”). 76
Extending these comparisons, federal policy set forth by NIDA, 77 the Surgeon General, 78 and the
President’s Commission on Combatting Addiction and the Opioid Crisis 79 classifies SUD as
chronic and relapsing disease. Viewing SUD as a chronic disease, relapse is not only possible,
but likely and may be triggered by exposure to environmental cues or reminders of the drug. 80
Volkow asserts relapse does not indicate a failure of treatment, but an indication that the person
requires an adjustment in treatment or needs treatment reinstated. 81 Classifying SUD as a
chronic neurological disease means persons with addiction will require long-term, repeated, and
even life-long treatment.82 Only about 10% of persons with SUD receive treatment, which the
Surgeon General identifies as a substantial treatment gap, calling for expanded access to
treatment.83 Treatment should address not only substance abuse, but additional co-morbid
disorders: approximately forty-one percent of persons with SUD also present with a co-occurring
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mental health conditions such as depression, anxiety, or ADHD, which requires additional
strategies for successful treatment. 84
B. Re-Examining the Brain Disease Model
Despite NIDA’s characterization of substance abuse as a chronic and relapsing brain
disease that fundamentally impairs individual choice, not all addiction scientists concur. In
Commonwealth v. Eldred, Assistant Attorney General Maria Granik compiled materials from
neuroscientists, psychologists and psychiatrists specializing in addiction that highlight flaws in
the brain disease model, which impacts not only future legal precedent but addiction medicine
and public health approaches to addiction. The Commonwealth’s brief and a supporting amicus
brief note central assumptions within the brain disease model – that SUD is similar to other
chronic diseases, persons with addiction experience dramatic neurological changes that
undermine their ability to resist the compulsion from abusing drugs is not universally shared
among experts.85 Psychologist Gene Heyman notes how we define addiction is critical for
devising strategies to reduce its harm through effective health policy, which should include
recognizing the role of personal agency and empowerment for recovery. 86
Addiction is Distinct from Chronic Diseases
Classifying addiction as a brain disease began as a noble strategy to extricate persons
with addiction from punitive moral judgment, expand research funding while legitimizing
addiction research, and allocate treatment coverage from insurance. 87 Yet the current model
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asserting addiction can be classified as a chronic relapsing disease similar to other diseases
presents a variety of detrimental constraints when considering precipitating factors of addiction
and the most appropriate methods of treatment. Psychologist and legal scholar Stephen Morse
notes unlike other chronic diseases such as cancer, hypertension, or diabetes, the primary
criterion for the addiction is behavioral.88 Addiction scientists note a person with other diseases
such as cancer cannot suppress the signs (“I will not have cancer today”), or a person with a
brain disease such as Alzheimer’s disease cannot will one’s self to remember on call. 89 Unlike a
person struggling to manage cancer or Alzheimer’s disease, no amount of reward or punishment
can alter the course of their disease. 90
Proponents of the brain disease model are correct in asserting many chronic diseases
involve individual choice in the progression of the disease (e.g. diet, exercise, stress management
for some conditions). 91 Yet pharmacological strategies alone are insufficient to address any
conditions that may have a behavior component whether addiction, hypertension or diabetes,
because they downplay the impact of social and psychological factors driving maladaptive or
destructive behavior. Narrow medical models of treating chronic disease are expensive, largely
ineffective, and constitute a poor model of effective medical intervention. 92 Truly successful
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interventions for many chronic conditions – along with addiction – also require a new
framework, such as the pioneering field of functional medicine that examines how to best
intervene to prevent and reverse disease by looking at correlations between choice and
empowering the public with strategies to take control of their health. 93 Independent of how we
classify addiction, effective health policy should examine whether the dominant model
sufficiently addresses the complexities involved in conditions with a behavioral component.
Addressing the behavioral component in addiction presents a distinct challenge because
abuse of illicit substances, unlike chronic diseases, presents a substantial health and safety hazard
not only to the person with SUD, but the general public. 94 A decision to repeatedly indulge in
doughnuts and a disdain for exercise may impact the progression of diabetes, but unlike a person
abusing illicit substances, it does not correlate to crimes affecting public safety and welfare such
as larceny, motor vehicle impairment, or child neglect and abuse. When a person’s behaviors
and choices directly impact public safety and welfare, then it is appropriate for social norms to
reproach actions that are reckless or harmful toward others.95 In instances such as
Commonwealth v. Eldred, when persons with SUD like Julie Eldred commit a crime, the law
(including drug-free conditions of probation) can be an effective tool for motivating people to
remain committed to stop using illicit substances and or engage in treatment. 96 Yet this is only
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the first part of the inquiry because compassion for persons suffering from addiction also
requires examining whether the current model to explain addiction captures its complexities, and
whether treatment interventions recommended in federal policy demonstrate successful
outcomes.
A Neurocentric View Minimizes the Importance Of Psychological And Social Factors
Precipitating Addiction
Psychiatrist Dr. Sally Satel and psychologist Scott Lilienfeld refer to the brain disease
model as “dogma,” and it constitutes the foundational message from NIDA and forms the basis
of medical school education and addiction counselor training. 97 According to Satel and
Lilienfeld, the brain disease model has dominated the field based on the assumption that if
scientists can identify biological roots, then a person has a disease. 98 Critics of the brain disease
model argue that designating the brain as the seat of addiction is “rooted in the dubious
assumption that neurobiology is destiny” 99 and the neurocentric view of addiction
problematically downplays psychological and social factors that contribute to addiction. 100
Though NIDA acknowledges stress constitutes a risk factor for substance abuse,101 focusing on
neurobiology ignores people’s reasons for abusing drugs, such as scare opportunity for
educational and economic growth, 102 pessimism, a culture that normalizes drug use, emptiness,
isolation, or lack of purpose. 103 Indeed, the World Health Organization cautions that medical
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models of substance abuse may not be a wholly positive development if it oversimplifies the role
of social policy in addressing risk factors of addiction. 104 In the case of Opioid Use Disorder,
focusing on circumstance and reason for use may also uncover a distinct category of persons
with physiological dependence rather than addiction. Reducing addiction to a neurobiological
flaw directly informs the basis for the dominant treatment model, which focuses on and searches
for a pharmacological cure. 105
Not all persons who initially use drugs develop an addiction, and both animal and human
studies demonstrate situational factors exert substantial impact. 106 Based on both animal and
human models, Volkow and Morales estimate about 10% of persons exposed to a drug will
develop an addiction. 107 Drug abuse may be precipitated by abuse, social isolation, or extreme
stress, which may remit with the removal or alternate management of those stressors. One of the
most frequently cited examples is the case of opiate addiction among U.S. Army personnel
during the Vietnam War. Critics of the brain disease model note that during the Vietnam War,
10-25% of U.S. Army enlisted personnel were addicted to opium or heroin. 108 To board the
plane and return from Vietnam, the U.S. Army required personnel to demonstrate a negative
urine screen.109 The majority of personnel passed the screen and boarded to return home on the
first or second try. 110 According to follow up studies by sociologist Lee Robbins, only 5% of
those who displayed addiction while in Vietnam relapsed within 10 months, and 12% relapsed

104

WORLD HEALTH ORGANIZATION, supra note 64, at 231.
Satel & Lilienfield, supra note 87, at 8.
106
Id.
107
Volkow & Morales, supra note 65, at 715.
108
Satel & Lilienfield, supra note 87, at 8; Marc Lewis, THE BIOLOGY OF DESIRE: WHY ADDICTION IS NOT A DISEASE
(2015) at 21-22.
109
Id.
110
Id.
105

21

within 3 years.111 This example illustrates the principle that addiction may be tied to situation,
circumstance, and context.
In addition to situational stressors, addiction scientists posits that addiction correlates to
developmental time frames relating to age and coping mechanisms. 112 Adolescents are more
likely to try illicit substances, 113 and both neuroscientist Marc Lewis and psychologist Gene
Heyman suggest substances initially provide an attractive balm to life’s obstacles or internal
conflicts by providing pleasure and relief. 114 This may constitute a self-destructive or
maladaptive strategy for addressing stressful circumstances or pressures that initially appears
appealing in the short term. 115 The difficulty, according to Satel and Lilienfeld, is that most
people would not express wish for the self-destruction that accompanies addiction: no one
“chooses” to become a person with drug addiction.116 Yet people do make a series of
incremental choices leading to a habit 117 that grows into an undesirable outcome of having an
addiction.118
Neurological Changes Do Not Preclude Choice and Change
The trajectory of drug abuse does modify neurological structure and function, but
disagreement exists in the scientific community of how to characterize the significance of these
differences. Some addiction scientists posit that the modifications in neurological structure and
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function arise in response to choice behavior and habit formation. 119 The initial decision to
abuse substances constitutes a narrow impulsive choice that focuses on immediate reward,
referred to as delay discounting (immediate rewards of pleasure and relief take precedence over
long term goals and considerations). 120 Every subsequent decision to use the drug strengthens
the synaptic connections of impulsivity and the compulsion to continue using the drug. 121 This
reinforces short-term gratification over long-term global consequences that include legal
concerns, familial consequences, economic pressure, or a desire for respect. 122
Even if subsequent decisions impact neural circuitry (or even impairs individual choice),
some addiction scientists distinguish this does not negate individual agency. Satel and Lilienfeld
acknowledge that SUD may constrain or impair a person’s capacity for choice, but it does not
destroy it.123 This distinction is critical: in Commonwealth v. Eldred, Eldred’s arguments rested
on the assertion that her SUD as scientific fact precluded her ability to refrain from substance
abuse – that is, she could not control her subsequent relapse with fentanyl despite the court’s
order to refrain from abusing illicit drugs while in treatment on probation for larceny. Some
addiction scientists convincingly demonstrate that persons with SUD do retain free will, can
reflect on multiple conflicting allegiances, and engage in self-reflection.124
Addiction science set forth in publications by NIDA and the World Health Organization
recognizes that contingency management (giving patients tangible rewards to reinforce positive
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behaviors such as abstinence) are highly effective. 125 In the alternative, the threat of negative
consequences such as professional sanction or legal repercussions can also motivate individual
choices.126 Heyman posits that persons with addiction reach a threshold of mounting
consequences and encounter psychological changes which include reflecting on identity, familial
role, legal concerns, and economic constraints that make heavy drug use no longer bearable. 127
Not all Persons with Addiction Require Treatment
Addiction scientists have found rates of remission are strongly influenced by multiple
external factors, most persons with SUD quit on their own without treatment, and SUD for most
people is not chronic and relapsing. 128 Persons who are married, more highly educated, or
concerned about negative legal repercussions are more likely to enter remission from substance
abuse.129 Rates of remission also correlate with external factors such as legal penalty, substance
availability, and ethical concerns. 130 To illustrate, according to historians the Harrison Narcotics

125

See Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition), NATIONAL INSTITUTE ON
DRUG ABUSE at 44-45 (Jan. 2018), https://www.drugabuse.gov/publications/principles-drug-addiction-treatmentresearch-based-guide-third-edition/preface; see also WORLD HEALTH ORGANIZATION, supra note 64, at 59-60
(discussing contingency management and cognitive behavioral therapy as effective strategies to unlearn dependence
behavior and learn more adaptive responses). See also August Holtyn et al., Behavioral Factors Predicting
Response to Employment Based Reinforcement of Cocaine Abstinence in Methadone Patients, 2(2) TRANSLATIONAL
ISSUES IN PSYCHOLOGICAL SCIENCE 122 (2016) at 2, 7 (discussing contingency management as one of the most
effective psychological approaches in treatment).
126
Amicus Curiae Brief of Eleven Addiction Experts, supra note 87, at 25-27 (discussing contingency management
and the example of pilots and physicians with addiction who must remain abstinent and are subject to random drug
screenings to retain their professional license), at 28-30 (discussing Powell v. Texas, 292 U.S. 514 (1968) wherein
Powell, an alcoholic who had been arrested 100 times for public intoxication made a conscious decision to have only
one drink the morning before his court appearance because he did not want to “pass out or be picked up” and miss
the court appearance); see also Larkin, supra note 50, at 71-73 (discussing the efficacy of Hawaii’s Opportunity
Probation with Enforcement Program).
127
Heyman, supra note 86, at 89.
128
Lewis, supra note 108, at 15 (stating addiction is not lifelong, but most persons quit substance abuse on their
own); Stanton Peele, No Matter How Much the “Chronic” Brain Disease Model of Addiction Indicates Otherwise,
We Know that People Can Quit Their Addictions – With Special Reference to Harm Reduction and Mindfulness, 4
ADDICTIVE BEHAVIORS REPORTS 97, 98 (2016) (stating every year a constant proportion of persons with addiction
remit); Heyman, supra note 114, at 1-2 (most persons with addiction quit on their own by age 30); Heyman, supra
note 112, at 31 (describing aging out and maturing out of addiction); Heyman, supra note 86, at 87 (most persons
with addiction to not seek treatment).
129
Heyman, supra note 112, at 51.
130
See, generally Heyman, supra note 86.
24

Tax Act reduced opiate use and addiction by as much as 50% on the population level,
demonstrating the impact of legal availability and price. 131 Availability also subjectively
influences craving: in one study, subjects with heroin addiction who knew they could obtain the
drug reported higher levels of craving than subjects who did not have access to heroin. 132
According to the National Epidemiologic Survey on Alcohol and Related Conditions, drug
availability also impacts both the length of addiction and the likelihood of remission from
substance abuse.133 Persons who have an addiction to licit substances, such as alcohol or
tobacco, demonstrate longer periods of substance abuse and are less likely to stop using the
substance.134 Each of these suggests persons with addiction make evaluations based on legality,
availability, access, and price which also strongly influences rates of remission.
Most people with an addiction stop on their own without treatment by the age of thirty 135
and addiction scientists note that entering remission constitutes the rule rather than the
exception.136 Annually, the proportion of persons with addiction remit on their own without
intervention and rates of asymptomatic recovery exceed 90%. 137 Rates of recovery remain
constant over time regardless of the time a person has engaged in substance abuse, which
supports the hypothesis that a lengthy period of addiction does not necessarily constitute a barrier
to remission. For most people, addiction is not chronic, and most persons with addiction do not
relapse.138 However, within the population subset that seeks treatment, the rates of relapse
remains high which skews subsequent studies examining remission, recovery, and relapse
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rates.139 The small subset of the this population with SUD often presents with additional
confounding issues, such as psychological co-morbid conditions, demographic differences, and
legal concerns. 140 Addiction scientists note that the population seeking treatment often
represents the sickest subset with people, and cautions that health policy decisions that generalize
this population are neither reflective nor accurate of the population of persons with SUD as a
whole.141
Careful assessment of these nuances should guide significant modifications in public
health approaches pertaining to treatment. If available research shows most persons with SUD
remit on their own without treatment, then treatment should not be mandated (for example, in the
criminal justice system) but rather offered to persons based on a tailored assessment of their
needs and how much and what type of treatment would be most appropriate.
The Role of Neuroplasticity in Recovery
Research on recovery and remission also demonstrates neuroplastic modifications
(changes in brain structure and function) from substance abuse in most instances are not
permanent.142 Instead, current scientific research shows persons with addiction can not only
make alternative choices143 and relearn mechanisms to respond to triggers of drug use, but
recovery creates novel neurological changes in the brain. 144
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Within the brain disease model, NIDA asserts substance abuse fundamentally modifies
the brain’s structure and function. 145 Yet the same principles of conditioned learning (repetitive
behaviors, association with reward, and new pathways in the brain) means therapies that target
biobehavioral learning processes also produce and correspond to neuroplastic modifications. 146
Current research demonstrates abstinence from substance abuse starts to produce changes in the
brain within a month. 147 Continued abstinence does not merely restore gray matter volume, but
in clinical human research it increased gray matter volume beyond the control comparison.148
Connolly and colleagues explain that abstinence requires reassertion of cognitive control and
behavioral monitoring that was diminished during substance abuse. 149 Elevated volume of gray
matter in these areas of the brain, according to Connolly and colleagues suggest that the brain is
not only capable of compensating in response to new demands such as maintaining abstinence,
but gray matter development in new areas suggests recovery constitutes more than merely
reversing gray matter loss and damage: people can guide their brains to learn and grow new
pathways.150
Self-Efficacy is a Crucial Component to Recovery
Classifying SUD as a chronic and relapsing brain disease potentially hinders recovery
because it fails to account for each person’s ability to exert control over his or her own life. 151
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Designating that all persons with SUD have an irreversibly diseased brain and will face a
lifetime of struggle is not only unsupported by current evidence, but may contribute to
helplessness and despair. 152 Reframing expectations with hope can assist persons with SUD to
see a valuable future, view themselves as agents of change, and believe they can develop the
skills for reflection to “reverse, reknit, and regrow” new neurological pathways through alternate
routines and habits leading to recovery. 153 Research suggests multiple effective therapies such as
contingency management, therapeutic communities, and social support programs may help
patients reconnect with their vision for a valued future. 154
Agency, neurological recovery, and the concept of self-efficacy are crucial ingredients
for persons with SUD to themselves believe in a different future. 155 While intended as an
extension of compassion, harm reduction policies that promote the use of alternate illicit
substances such as marijuana or supervised consumption sites not only undermine the concept of
self-efficacy and facilitate the circumstances for persons with SUD to continue inflicting selfharm, but also relay the destructive and potentially self-fulfilling message that some persons with
addiction are beyond recovery. 156
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C. Why Terminology Matters: Physiological Dependence, Addiction, and Substance
Use Disorder
The considerations of whether persons with SUD would benefit from treatment, whether
they relapse, and what factors influence these questions requires greater precision when
describing both the population and the condition. Research suggests not all persons with SUD
progress to unremitting addiction, and not all persons with OUD specifically should be swept
into the category of persons with an addiction but may encompass distinct populations that
compels a different approach.
Shifts in the Diagnostic and Statistical Manual: No More Distinct Categories to Describe
Addiction
Both federal policy and diagnostic classifications have addressed the matter of
terminology and how to address the concept of addiction and terminology. Until recently,
addiction scientists distinguished between physiological dependence and substance abuse or
addiction. Drugs including opioids may cause physical and psychological dependence resulting
in symptoms of withdrawal which is distinct from addiction, or a compulsive and intense desire
to continue using the drug even at the expense of serious adverse consequences. 157 Reuben
Baler and Nora Volkow of NIDA also recognize that only a small portion (about 10%) of
persons who abuse substances progress to addiction. 158
Although addiction is not a diagnostic classification, until 2013 the American Psychiatric
Association in the Diagnostic and Statistical Manual (DSM) recognized two distinct categories
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of substance abuse and substance dependence. 159 Criteria for substance abuse entailed harmful
use of substances that resulted in harm to others, such as neglecting life roles, hazardous use,
legal problems, and interpersonal or social problems.160 To compare, substance dependence
referred to harm to one’s self resulting from physical and physiological dependence, such as
tolerance, withdrawal, using larger amounts of a substance, devoting more time to using the
substance, experience of physical or psychological problems from using the substance, and
repeated attempts to quit. 161
In 2013, The American Psychiatric Association published the DSM V, which merged two
previously distinct categories into a singular category of substance use disorder, 162 vastly
increasing the breadth of the persons who may have developed a tolerance to a drug, experience
withdrawal, and are trying to stop using the drug into the same broader category of a person with
intractable addiction who experiences social and legal problems and may have no desire to
discontinue the addiction.
The Office of National Drug Control Policy’s Memorandum on Addiction Terminology
In 2017, Director of the Office of National Drug Control Policy (ONDCP) Michael
Botticelli issued a Memorandum calling to modify key terminology relating to addiction. 163
According to ONDCP, the public associates disfavor with the terminology “substance abuser,” it
provokes negative attitudes among health professionals, and it may deter persons who need
treatment.164 Referencing the modification in the DSM, ONDCP asserted “substance use
disorder” is the clinically accurate term, because drug “habit” and “drug abuse” incorrectly imply
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the person has a choice to stop, which causes confusion because the person instead requires
treatment to stop or reduce his or her substance use to a “safer level.” 165
Both the modification in the DSM and the ONDCP’s call to relabel previously distinct
categories has dramatic implications for considering how to address patient populations
accurately and determining as a matter of health policy what course of clinical intervention is
appropriate. For example, the term opioid use disorder collapses both persons with intractable
addiction to heroin and prescription opioids versus persons who developed physiological
dependence to prescription opioids. This has significant impact for the scenario when a person
was prescribed an opioid and is unsuccessfully attempting to discontinue using it, but faces
painful physical and physiological withdrawal and the prescribing clinician is unable or lacks
appropriate resources to assist the patient to discontinue the medication. 166 Physician Dr.
Andrew Kolodny notes opioids produce both physical and psychological symptoms when a
patient attempt to discontinue the medication. 167 A patient may experience physical withdrawal
symptoms such as nausea, vomiting, sweating, muscle aches, but also agitation, anxiety,
insomnia and a feeling of “impending doom.”168
Accurately Identifying the Patient Population and Its Needs: Iatrogenic Opioid Dependency
ONDCP’s Memorandum also discounts pertinent differences among population groups
based on type of substance abuse. NIDA recognizes that heroin use is rare in prescription drug
users, and only a very small percent (4%) of persons who have prescription opioid dependence
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begin abusing heroin. 169 Of this population that switches from heroin from prescription opioids,
these persons are frequently polysubstance abusers of other illicit drugs. 170 Of persons who
misused prescription opioids in the 2000s, 75% reported their first opioid was a prescription
drug.171 Demographic characteristics based on race and socioeconomic status on a population
level differ among persons abusing heroin and other opiates (younger men from minority races
living in urban areas) versus persons with prescription opioid dependence (older white persons in
rural and suburban areas).172 These demographic shifts have led to outcry in the media alleging
racial bias as a motivating reason for approaching opioid dependency as a medical condition
requiring treatment rather than a matter of public safety and crime. 173 As described supra in Part
I, even though substance abuse and crime may be interrelated, persons are not penalized for
either physiological dependence on a substance or having an addiction, but their decision to
commit a crime.
These claims further ignore the crucial distinction the healthcare system played in
creating a class of patients with iatrogenic opioid dependency. Patients use of, and dependence
on, prescription opioids in many cases began with a legitimate therapeutic prescription after
seeking medical care from a physician. 174 As prescriptions for opioids nearly tripled from 1991
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to 2011, overdose deaths also near tripled over the same time period. 175 Physician Dr. Anna
Lembke aptly describes the confluence of factors stemming from industry exerting influence on
physicians to overprescribe opioids to more patients. 176 This led to creating a new class of
patients with iatrogenic opioid dependence: what Kolodny describes as a “perfect patient”
attempting to discontinue a prescribed medication experiences who not only experiences acute
withdrawal, but months of extended withdrawal with difficulty sleeping, irritability, and
unrelenting depression.177 Without assessing the patient population and its specific needs,
expanding the current treatment model would entail sweeping persons with iatrogenic
physiological dependence into the same treatment category as persons with addiction.
Parallels Between Opioid Marketing and Claims Relating to MAT
Lessons from drug marketing promises that led to the opioid crisis highlight a number of
considerations that are directly relevant when asking whether prescribing a different class of
medications in MAT constitutes the most appropriate policy response. In 2007, Purdue
Frederick Company pled guilty to criminal charges of misbranding OxyContin with the intent to
defraud or mislead, which is considered a felony under the Federal Food, Drug and Cosmetic
Act, wherein Purdue paid $634.5 million in monetary sanctions. 178 Though the substantive
details of this case and allegations of ongoing deception 179 are outside the scope of this
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discussion, the case raises salient parallels of how financial interests can shape medical practice
and perception of what constitutes appropriate medical care. 180
Purdue proffered a variety of claims that bear striking similarity to claims currently
percolating in scientific and scholarly literature relating to maintenance medications utilized in
MAT. First, corporate interests expand the pool of potential patients and designate treatment as
a medical need that should not be denied. 181 This ignores research that shows pharmacological
intervention may not be effective while other less risky modalities may provide benefit. 182
Second, corporate interests assert pharmacological intervention constitutes the most effective
solution and downplay risk. In educational materials, manufacturers may bolster these claims by
specific promises that the medication is less likely to cause tolerance and withdrawal compared
to other substances, is “less addictive,” does not cause euphoria, and is less likely to be abused or
diverted.183 In the case of medications used in MAT, these are exactly the terms NIDA and
SAMHSA uses to describe two medication used in MAT, methadone and buprenorphine, and
distinguish them from other prescription opioids. Few ask the pertinent question of whether the
evidence indeed exists to support claims of appropriateness, safety, and perceived benefit. 184
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In January 2019, media outlets published a full unredacted complaint Massachusetts
Attorney General filed against Purdue Pharma. 185 This lawsuit alleges, among other claims
relating to fueling the opioid epidemic in the U.S., that Purdue Pharma actively formulated a
strategy to capitalize on expanding into the “attractive market” of selling treatments for patients
with OUD.186 Notably, Richard Sackler part of one of the co-founding families behind of Purdue
Pharma, is listed as joint patent holder on a new formulation of buprenorphine. 187 According to
the State’s Complaint, Purdue Pharma planned for “a joint venture controlled by the Sacklers to
sell the addiction medication suboxone,” outlining Purdue Pharma’s business strategy Project
Tango: “patients on opioids could now be used to sell treatment for opioid addiction.” 188 Based
on Project Tango’s projections, 40-60% of patients would relapse, which translated to long term
use of a buprenorphine formulation. 189 This unconscionable conflict of interest merits further
scrutiny when examining the scope, prominence and promises of MAT.
III. MEDICATION ASSISTED TREATMENT
This section will describe the view set forth by NIDA, SAMHSA, and the Office of
National Drug Control Policy that MAT constitutes the most effective method of treatment for
OUD. It will provide an overview of three types of FDA approved medication (1) methadone,
(2) buprenorphine, (3) and naltrexone, including legal classification, prescribing requirements,
and potential risks or adverse effects.
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A. The Prominence of MAT
The Surgeon General’s Report on Alcohol, Drugs, and Health states there is “one clear
conclusion:” if SUD constitutes a chronic but treatable disease, then it requires expanded medical
intervention.190 In the U.S., the FDA has approved three classes of medications to treat persons
with OUD in MAT: methadone, buprenorphine, and naltrexone.191 NIDA maintains medication,
along with behavioral therapy constitutes the most effective treatment for opioid use disorder. 192
ONDCP goes further, asserting medication does not merely assist with psychosocial services, but
is itself a central component of evidence-based practice. 193 The American Society of Addiction
Medicine (ASAM) issued specific Practice Guidelines regarding the use of medications in
treating opioid use disorder, provides dosing guidelines, and recommends implementing a plan
for psychosocial treatment in addiction to pharmacological treatment. 194
Methadone
In the 1960s, physicians Drs. Vincent Dole and Marie Nyswander piloted the use of
methadone as a replacement drug for a small population of persons with intractable heroin
addiction.195 Dole and Nyswander hypothesized addiction could be reduced to biochemical
deficiency, theorizing persons with intractable intravenous heroin addiction suffered from a
metabolic disruption wherein they “needed narcotics in a visceral way.” 196 By providing an
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exceptionally high dose of a substitute opioid in a clinical setting, physicians could “correct” a
“neurological derangement.”197 Methadone maintenance, according to Dole, was corrective but
not curative.198
Methadone is a synthetic full opioid agonist, which binds to and activates the same opioid
receptors as heroin, morphine, and opioid pain medications. 199 It is designed for a slower and
more controlled release to prevent cravings and withdrawal symptoms over a longer time
duration.200 NIDA maintains methadone does not produce euphoria at therapeutic doses, patients
receiving methadone do not appear “high” based on their tolerance to the drug’s effects, and are
able to function normally to attend school, work, and engage in activities of daily life. 201
Under the Controlled Substances Act, methadone is a Class II controlled substance,
which means despite an accepted medical use, it has a high potential for abuse and may lead to
severe psychological or physical dependence. 202 The Controlled Substances Act requires
practitioners who dispense, administer, or prescribe methadone or buprenorphine to register with
the Drug Enforcement Administration. 203 Practitioners also must maintain records of inventory
to track prescribing for both methadone and buprenorphine as a mechanism designed to prevent
diversion.204 When used in the context of opioid treatment, practitioners may only provide
methadone through an Opioid Treatment Program (OTP) that is certified and complies with
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requirements set forth by Substance Abuse and Mental Health Administration (SAMHSA). 205
With limited exceptions, providers at OTPs may only administer methadone to patients at the
facility. Federal regulations permit “take home” doses of methadone for weekends, holidays,
and based on the provider’s discretion when reviewing a record of a patient’s treatment
compliance.206
NIDA states health professionals have successfully used methadone for forty years.
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2009, Richard Mattick and colleagues reviewed studies examining the use of methadone
maintenance versus no methadone maintenance for persons with opioid dependence. 208 Mattick
and colleagues found patients receiving methadone maintenance showed a higher rate of
retention in treatment, reduced heroin use and concluded health professionals should support
methadone maintenance for persons with heroin addiction.209
Use of methadone carries a variety side effects and risk of adverse events. Side effects
may include dizziness, sedation, nausea, vomiting, sweating, confusion, agitation, dysphoria, and
insomnia.210 Risks also include life threatening QT prolongation (a heart arrhythmia) and similar
to other opioid analgesics, administration of methadone even in the prescribed amount can cause
respiratory depression and death. 211
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Methadone has unique pharmacological properties that require cautious administration.
The analgesic effect of methadone lasts about 4 to 8 hours, but it remains in the body for 8 to 59
hours, binding to tissues including the brain. 212 In risk management materials, SAMHSA has
warned the combination of methadone’s long half-life and slow elimination can result in the fatal
accumulation of methadone in patients, leading to iatrogenic overdose. 213 Methadone also may
exert neurotoxic effects, reduce gastrointestinal motility leading to constipation, suppress the
immune system, and impact the endocrine system which may manifest as insulin imbalances,
impotence, erectile dysfunction, amenorrhea, or infertility. 214 The FDA approved package insert
for Methadose, the oral liquid used by OTPs also provides a warning statement that methadone
may impair the patient’s ability to drive or operate heavy machinery. 215
Despite the profile of risks and adverse events, health professionals maintain “essential
questions of safety and efficacy have been definitively answered” and methadone offers a safe
and effective treatment for persons with addiction because it normalizes patient function with
minimal psychoactive impairment. 216
Buprenorphine
Buprenorphine is a partial opioid agonist, and binds to the same receptors as other
opioids but activates them less strongly. 217 It is also designed to reduce cravings and withdrawal
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at therapeutic doses, and NIDA states it does produce euphoria based on patient tolerance and
dosage.218 Some formulations of buprenorphine combine buprenorphine with naloxone, an
opioid antagonist to function as an abuse deterrent. 219 As a partial agonist, it is designed to block
the high from additional opiates and SAMHSA asserts buprenorphine carries a lower risk of
abuse or diversion based on its “ceiling effect.” 220 SAMHSA states buprenorphine assists
persons with opioid abuse disorder regain normal, healthy lives, and permits patients to function
normally.221
Under the Controlled Substances Act, buprenorphine is a Class III controlled substance,
which means the DEA has determined it has less potential for abuse than a Class II substance
such as methadone. 222 Buprenorphine has an accepted medical use, and abuse of it may lead to
moderate or low physical dependence and high psychological dependence. 223 Buprenorphine
comes in several forms, including daily pills, a sublingual film, and a sixth month injection. 224
Physicians may prescribe buprenorphine through an OTP certified by SAMHSA or through
physician offices for addiction treatment pursuant to specific requirements. 225 The Drug
Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act permits
physicians, qualifying nurse practitioners, and physicians’ assistants to obtain a waiver from the
Secretary of Health and Human Services to prescribe and dispense buprenorphine in outpatient
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settings, such as physician offices rather than traveling to receive a daily dose of medication at
an OTP.226
Proponents of MAT and buprenorphine note that eliminating the need for daily clinic
visits expands access for patient to receive medication used in MAT. 227 Patients treated with
buprenorphine are more likely to stay in treatment compared to patients receiving placebo, and
less likely to abuse opioids than patients receiving no form of treatment. 228 Comparisons
demonstrate similar rates of efficacy for either methadone or buprenorphine when the prescribed
at a sufficient dose and duration. 229
Side effects from buprenorphine include headache, nausea, vomiting, sweating,
constipation, withdrawal symptoms, anxiety, depression, and insomnia. 230 Additional adverse
risks include hepatic events, respiratory depression, and overdose, which is more likely to occur
if a patient combines buprenorphine with central nervous system depressants such as alcohol or
benzodiazepines.231 The FDA approved package insert for one formulation, Subutex, carries
specific warnings of its potential for dependence and abuse along with a warning Subutex may
impair the patient’s ability to drive or operate machinery. 232
Naltrexone
Naltrexone is an opioid antagonist, which blocks the effects of opioids by binding to
opioid receptors which is designed to block euphoria from opioid drugs. 233 It may also block
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endogenous opioid peptides. 234 Naltrexone is designed to prevent relapse following
detoxification from opioids.235 If a patient begins taking naltrexone prior to detoxification, the
patient may experience withdrawal symptoms.236 Naltrexone comes in daily pill form or a once
monthly injection by the brand name Vivitrol. 237 Naltrexone is not designed to stop drug
cravings, is not designed as an aversive therapy, and a patient may be able to surmount the
pharmacological barrier. 238 If a patient abuses opioids during treatment with naltrexone, the
patient’s tolerance for the opioid may decrease, which increases the risk of overdose. 239
Naltrexone is not an opioid and is not classified under the Controlled Substances Act, so
it may be prescribed by any physician, whether through an OTP or a physician office as part of
MAT.
NIDA states there is insufficient evidence that oral naltrexone is an effective treatment
for opioid use disorder, and instead recommends injectable naltrexone, which one clinical trial
demonstrated decreased opioid abuse and improved treatment retention. 240 Research shows
fewer patients utilize naltrexone compares to methadone or buprenorphine, low patient
adherence to naltrexone and high rates of attrition.241 One research study by Dr. Joshua Lee and
colleagues compared the effectiveness of a buprenorphine-naloxone combination against
injectable naltrexone, measuring treatment retention and opioid abuse in a research trial, finding
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similar outcomes for each metric.242 Physicians who specialize in addiction, including Dr.
Andrew Kolodny, highlight a substantial percent (28%) of study subjects withdrew from the
initial clinical trial during the detoxification phase, leaving these patients susceptible to relapse
and overdose and potentially misrepresents the conclusion that both medications offer similar
rates of efficacy.243
Side effects from injectable naltrexone include nausea, vomiting, injection site reaction,
muscle pain, insomnia, and hepatic abnormalities.244 Additional adverse events include hepatic
toxicity, injection site necrosis, eosinophilic pneumonia, depression, and suicidality. 245 The FDA
approved package insert for one formulation, Vivitrol, also warns of risk of dizziness, sleepiness,
and the potential to impair the patient’s ability to drive or operate machinery. 246
B. “Consensus” on the Efficacy of MAT
Federal policy asserts there is “consensus” 247 in the medical community that MAT plays
a critical role in the treatment of persons with opioid use disorder and it constitutes the most
effective form of treatment. 248 NIDA states that patients receiving MAT are more likely to
reduce their use of opioids, remain in treatment, and reduce their involvement in the criminal
justice system.249 The Surgeon General notes MAT assists persons with an opioid use disorder
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to control their symptoms of withdrawal and craving and helps patients return to a healthy life. 250
To achieve the best outcomes, providers should use MAT in conjunction with behavioral therapy
measures.251 SAMHSA recommends patients should use medications as long as it provides
benefit, cautioning that patients who discontinue medication generally return to illicit opioid use
and healthcare policy should prioritize patient access, utilization, and expansion of MAT. 252
NIDA, SAMHSA, and the Office of National Drug Control Policy 253 each issued specific
statements asserting it is a “misconception” that MAT substitutes one substance use disorder for
another, lamenting this perspective has hindered the adoption of evidence-based treatments.254
SAMHSA maintains patients using replacement opioids as part of MAT receive a safe and
controlled level of medication and the appropriate dose exerts “no adverse effects on a person’s
intelligence, mental capability, physical functioning, or employability.” 255 NIDA asserts patients
receiving replacement opioid agonists do not experience euphoria because they have developed a
tolerance.256 In a 2016 report, the Government Accountability Office stated abstinence-based
treatment often fails, is less effective than MAT, and argued hesitation or opposition to MAT
indicates a “lack of understanding” of addiction and inaccurate beliefs. 257 Friedmann and Suzuki
argue extensive research shows pharmacotherapy constitutes the most effective treatment
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specifically for OUD and should constitute the first line standard of care, replacing any treatment
programs that offer detoxification and therapy. 258
IV. CRITICAL ANALYSIS OF THE EVIDENCE SUPPORTING MAT
MAT may indeed work for some patients, particularly if the patient tolerates the
medication without adverse effects and the provider offers comprehensive behavioral treatment.
But promoting MAT as blanket federal policy, or even as a first line long term treatment,
requires critical analysis. This section describes how claims pertaining to MAT’s efficacy are
supported by partial metrics and federal policy has downplayed problematic outcomes such as
high rates of continued opioid and polysubstance abuse, potential for dependence or addiction to
the replacement medication, and risk of serious physical and neurological outcomes. Financial
entanglements between industry and government appear to exert influence on federal policy
supporting the expansion of MAT for all persons with OUD, yet an independent review by the
Cochrane Collaboration distinguished little evidence exists for providing pharmacotherapy to all
persons with opioid dependence.
A. Declarations of MAT’s Success Downplay Important Metrics
Statements asserting that MAT constitutes the most effective treatment contains a
number of potentially misleading caveats: some studies support this proposition by comparing
MAT to detoxification 259 rather than treatment and do not address the significance of continued
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substance abuse.260 One commonly cited study by Karen Sees and colleagues did compare MAT
against treatment (where the detoxification group was required to attend therapy sessions) and
reported MAT increased retention and reduced opioid use.261 Yet this claim requires further
examination: despite a slight decrease in opioid use among the MAT group, opioid use in both
groups remained “consistently high,” and both groups continued polysubstance abuse of both
opioids and cocaine, which Sees and colleagues noted “remains a concern.” 262 Though rates of
substance abuse vary over time and by study, rates of continued opioid abuse among subjects
enrolled in MAT range from over 50% to 89.5%, even after being enrolled in MAT for several
months.263 Indeed, Nielsen and colleagues concluded there appears to be no significant
difference in days of unsanctioned opioid use among study groups who receive MAT versus those
who do not.264
Research cited to support the efficacy of MAT also demonstrates consistently high rates
of other types of polysubstance abuse across study groups, including among subjects receiving
MAT.265 Additional research shows subjects enrolled in MAT abuse multiple other licit and
illicit substances in addition to opioids including alcohol, cocaine, and cannabis. 266 Sees and
colleagues assert rates of polysubstance abuse do not appear to be related to inadequate dosing of
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maintenance medication. 267 Discounting significant continuing opioid or polysubstance abuse
among persons enrolled in MAT should trigger a re-assessment of blanket declarations of
efficacy.
Both media reports and case law bolster these data showing patients enrolled in MAT
continue to abuse opioids and or engage polysubstance abuse. One patient who was enrolled in
MAT and received a prescription for Suboxone (buprenorphine/naloxone) commented it “did
nothing but prolong my death…I was just taking other drugs with it and it was really just a BandAid.”268 Similarly, investigations into OTPs by the New York Times shared a father’s story, who
reported despite his son’s assertion that Suboxone worked for him, his son overdosed five times
by abusing other substances while in MAT, eventually succumbing to a fatal overdose. 269
Case law portrays similar findings: in Taylor v. Smith, Glenda Ennis, a patient in a
methadone maintenance program, stated repeatedly she had no desire to stop any of her
polysubstance abuse, and continued to abuse cannabis and illicit benzodiazepines while enrolled
in MAT.270 Similarly, in Lingren v. Pinnacle Recovery Services, methadone maintenance patient
Vanessa Brigan continued illicit substance abuse by not only drinking her daily dose of
methadone, but injecting additional doses of methadone, and simultaneously abusing cannabis. 271
The court in Taylor v. Smith concluded MAT facilitated Ennis to receive methadone not in lieu
of illegal drugs, but in addition to them.”272
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Many studies compare retention in treatment as a metric of success, but presuming
treatment retention equates to success reveals conflicting and troubling evidence. While Mattick
and colleagues review asserted that MAT constitutes an effective intervention, it found no
statistically significant differences in criminal involvement or mortality. 273 Several studies
conflict with the Surgeon General’s claims that MAT helps persons return to a productive life,
finding continued psychosocial dysfunction and rates of marginal employment or
unemployment.274 One significant barrier to employment and psychosocial functioning rests
upon patients’ ability to conduct activities of daily living, such as driving, working, going to
school, and engaging in family life without significant impairment such as experiencing
euphoria, craving, and symptoms of withdrawal. 275
B. Evidence Does Not Support the Proposition that MAT Permits Patients to
Function Normally and Promotes Recovery
MAT Does Serve as Medically Sanctioned Substitute Opioid with Serious Risks for Dependency
Despite rhetoric in federal policy asserting MAT does not constitute replacing or
substituting one SUD for another, these claims are not supported by pharmacology, legal
classification by the DEA, or numerous first person patient reports. As opioid agonists, both
methadone and buprenorphine occupy the same receptors as other substances such as heroin or
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oxycodone.276 Though NIDA denies patients receiving methadone and buprenorphine
experience euphoria, both FDA and DEA product labeling caution against the opposite: both
controlled substances are capable of producing significant euphoria even in persons with
tolerance.277 In a graph illustrating sustained activation of opioid receptors (euphoria), NIDA
compares the relative euphoria of heroin to methadone, buprenorphine, and naltrexone. 278 The
graph shows buprenorphine as a partial opioid agonist produces less euphoria relative to heroin,
but also shows methadone produces the same level of euphoria as heroin, but sustains this
activation for a longer duration relative to heroin. 279 Patient reports collected in research,
SAMHSA provider educational materials, 280 and patient accounts reported in the media confirm
patients request higher doses specifically to experience euphoria, 281 become “desperate”282 in
seeking more agonist medication in greater dosages, and allege “it’s easy to game the
system…[and receive] as much as you want.” 283
Research also supports the premise that MAT may not reduce cravings: many persons
enrolled in MAT abuse the prescribed agonist itself (e.g. injecting methadone or buprenorphine)
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in addition to continuing concurrent polysubstance abuse.284 This suggests a deficiency in the
premise of MAT – patients are still experiencing a compulsion and drive to abuse opioid
agonists, including the prescribed opioid agonist, for pharmacological effect. Indeed, in 2016, an
opinion piece the New York Times described patients attempting recovery through MAT who
became dependent on Suboxone, and developed an addiction to the medication itself. 285
Patients are also diverting the medication into the illicit market. 286 Despite NIDA’s
assertion that diversion is rare and merely occurs for therapeutic purposes, 287 recent research,288
the Drug Enforcement Administration (DEA), 289 and the Department of Justice290 suggests
diversion may constitute an increasing problem. 291 In 2009, the National Forensic Laboratory
Information System of the DEA published a special report demonstrating the explosion of
diverted methadone and buprenorphine between 2003 and 2008 during the period when patient
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enrollment in MAT increased in response to opioid dependency. 292 During this time, diversion
of buprenorphine increased 250-fold into the illicit market.293
Finally, patients who want to discontinue maintenance medication may find their
treatment facility or individual practitioner may not provide a clear plan of how to stop. 294
SAMHSA specifically recognizes many OTPs do not provide a pathway for its patients to go
medication free based on a justification of “poor outcomes” and acknowledges opioid agonists
do result in patient dependence. 295 Patients feel resigned to taking a maintenance medication
“maybe forever” according to one physician because if they stop, they encounter severe
symptoms of withdrawal and become physically sick.296
MAT Can Produce Physical, Neurological, and or Psychological Harm That Hinders Recovery
The extensive and serious adverse effects for each of the three classes of medications
used in MAT should not be dismissed as infrequent and may influence patients’ ability to engage
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in activities of daily life. In one study, over half of patients enrolled in methadone maintenance
programs experienced depression, fatigue, and headaches, which negatively impact patients’
subjective assessments of quality of life. 297
Research suggests both opioid agonist and opioid antagonist medications used in MAT
also pose risks to neurological and or psychological functioning.
Wei-Che Lin and colleagues demonstrated patients enrolled in MAT who received an
opioid agonist experience prominent adverse effects on multiple cognitive functions, experience
increased rates of depression and suicide, and experience a lower quality of life. 298 Opioid
agonists negatively impact memory processing, impair short term memory, impair visuo-spatial
attention, reduce cognitive speed. 299 Research shows opioid agonists produce changes in both
white matter and gray matter in the brain, resulting structural and functional abnormalities. 300
Chronic exposure to opioid agonists may lead to apoptosis (death) of neuronal cells and
demyelination (impaired connectivity within the brain’s synapses), which has been connected to
behaviors including impulsivity, lack of self-control, and intolerance for cognitive complexity. 301
Notably, research correlates this neurological damage to duration and dose of MAT, not preexisting differences or damage from illicit opioid abuse.302 Wei Li and colleagues summarize
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these findings as evidence that MAT induces a type of brain disease that may substantially
impair enrolled patients. 303 This research suggests MAT does not promote neurological
recovery, but rather extends neurological dysfunction and may hinder behavioral therapy options
that rely on new neurological growth, cognitive judgment, and discernment.
Opioid antagonist naltrexone’s inherent pharmacology likely impacts low adherence
because, as an opioid antagonist, it may block the effect of endogenous opioids, endorphins, and
enkephalins.304 Patients may be more likely to experience pain, depression, and thoughts of
suicidality.305 Research shows naltrexone blocks or reduces the joy from life activities: such as
the warmth of feeling connected to others, pleasure from delicious food, and a positive mood
from exercise.306 Activities that provide alternate outlets such as exercise 307 and therapeutic
communities 308 show excellent promise as potential therapies to reconnect and engage. Yet,
patients who adhere to naltrexone treatment may encounter difficulty in attempting to find
alternate strategies, goals, and activities if they find their activities lack purpose and joy.
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C. Financial Conflicts of Interest Have Significantly Driven Expansion of MAT
Benedikt Fischer of the Centre for Addiction and Mental Health highlights the impact of
corporate involvement in Canadian federal policy promoting MAT as a first line treatment
despite lack of evidence for this patient population and serious adverse effects. 309 In other
scholarship, I’ve noted the strong financial conflicts of interest between clinical care standards
and prescribing practices, and similar financial interests appear to influence federal policy here in
the U.S.310 The American Society of Addiction Medicine that provides clinical guidelines for
three types of maintenance medications as appropriate treatment choices (rather than alternate
forms of comprehensive treatment) receives industry funding from multiple manufacturers of
medications used in MAT. 311 Industry funding may impact prescribing and policy to promote
both opioid agonists and opioid antagonist medications.
The New York Times reported on the public private partnership between NIDA and
Reckitt Benkiser to conduct clinical trials on buprenorphine, which NIDA and the ONDCP
viewed as an improvement to methadone. 312 Charles O’Keefe, a former White House Drug
Policy advisor also involved with Reckitt Benkiser, lobbied Congress to amend federal law to
facilitate increased prescriptions for buprenorphine. 313 States began to offer financial incentives
or subsidies to increase the pool of providers, which correlated with more individual practitioners
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and OTPs offering buprenorphine. 314 Entanglement between industry and federal policy has
overshadowed concerns initially raised by the DEA and FDA pertaining to potential for
dependency and diversion relating to buprenorphine. 315 MAT increases profit not only for the
pharmaceutical sector, 316 but for physicians 317 and OTPs, which have emerged as one of the most
profitable sectors in healthcare with high profit margins. 318
According to the Center for Responsive Politics, in 2016 Alkermes spent $4.4 million for
aggressive lobbying to brand Vivitrol (naltrexone) as a “nonaddictive medication” alternative to
opioid agonists.319 Marketing to law enforcement and policymakers, Alkermes drafted sample
state legislation permitting community corrections grant priority for programs that offer
alternative sentencing programs, which may include “nonaddictive medication” for opioid
dependency320 and marketed Vivitrol directly to drug court professionals as a method to directly
expand its market reach. 321
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The criminal justice setting specifically warrants special consideration based on the
court’s influence and potential for coercion. If offenders do require treatment, it must be
evidence-based on appropriate outcome data, not financial entanglements and misleading
metrics. According to the World Health Organization, implementing any medication
requirement in the criminal justice setting as a condition of parole or probation triggers serious
human rights considerations. 322 Financial entanglements, forceful lobbying, and the unique
pharmacological profiles of medications used in MAT warrant inquiry whether these
medications would in fact be effective, humane, and ethically appropriate compared to alternate
models for the criminal justice setting such as HOPE or treatment alternatives.323
D. Expanding MAT to all Persons with Opioid Use Disorder is Not Supported by
Current Evidence
In Dole and Nyswander’s work, MAT using methadone began an experimental method to
reduce mortality and relative illicit drug abuse among persons with intractable heroin addiction.
Mattick and colleague’s review of research examining outcomes of patients enrolled in MAT
used studies of patients with a heroin addiction, not patients with other types of OUD. 324 In
2016, the Suzanne Nielsen and colleagues published a review of studies that focus on the more
precise question of whether MAT is effective for persons with OUD. 325 Nielsen and colleagues
found “very limited studies” and low to moderate quality evidence supporting the use of
pharmacotherapy for opioid dependence. 326 Notably, Nielsen and colleagues also reiterated that
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persons with heroin addiction appear to differ in important ways from persons with an opioid use
disorder.327
Benedikt Fischer echoes Nielsen and colleague’s finding, asserting many persons with
OUD are characterized by clinically relevant differences such as short-term or tangential
involvement with prescription misuse. 328 Fischer and colleagues predict adverse effects from
MAT such as negative neurological changes, depression, and mortality will create a new
epidemic of iatrogenic harm from medical intervention and assert evidence instead supports an
individualized stepped approach where many patients would benefit from medication taper
supported by behavioral therapy.329
The evidence described above outlines numerous deficiencies supporting the proposition
that MAT constitutes a safe, effective, and appropriate solution for either addiction or
physiological dependence.
V. Shortcomings Of Current Opioid Treatment Programs And Implications For Public
Health And Safety
This section will consider the implications of expanding MAT to all persons with Opioid
Use Disorder by examining massive shortcomings relating to the regulation of Opioid Treatment
Providers (OTPs), discrepancies in treatment quality, and why case law compels a fresh
examination of the current treatment paradigm.
A. Glimpses of a Problem: OTP Noncompliance and Substandard Care
Recent media report, lawsuits, and case law suggest the current framework for MAT may
pose serious health risks to both patient well-being and public safety. Multiple reports describe
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patients enrolled in MAT have died from either actively overdosing, 330 or died from iatrogenic
overdose wherein the patient ingested an opioid agonist as prescribed and died from medication
toxicity.331 Compliance investigations and survey research of OTPs reveal some patients are
enrolled in more than one OTP facility and receive multiple prescriptions, but physicians or OTP
facilities do not check prescription drug monitoring databases. 332 Media reports have also
highlighted concerns relating to the sufficiency of treatment provided at OTPs, such “dose and
go” treatment center that line up patients to receive medication but fail to provide behavioral
therapy or counseling despite a federal requirement to do so. 333 Across the country, media
reports detail how patients at OTPs who receive their medication and leave the facility impaired,
only to drive away and cause fatal motor vehicle accidents.334
Research by public policy scholars Mary Wickersham and Stephanie Basey along with
the sheer amount of media reports, lawsuits, and case law suggests the reported cases of patient
injury, OTP clinic mismanagement, and harm to the public constitutes the tip of the iceberg to a
much larger problem. From 1996 to 2012, the number of OTPs doubled, and in June 2018 HHS
announced the availability of $350 million in new funding to expand access to substance use
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disorder and mental health services including MAT and OTPs.335 Expanding the current model
for assuring the quality of OTPs translates to the potential for more patient exposure to facilities
without effective oversight to their quality.
B. Regulation of OTPs
OTPs are regulated on both the federal and state level.336 Specific requirements set forth
in 42 C.F.R. Part 8.12 designates that OTPs are required to be certified by SAMHSA and have a
valid accreditation status; OTPs may be accredited by either the state or a private accreditation
body, such as the Commission on Accreditation of Healthcare Facilities (CARF). 337 According
to SAMHSA, the regulations set forth minimum acceptable standards for the operation of OTPs,
but are not intended as the professional standard of care. 338 The regulations and corresponding
guidance issued by SAMHSA outline details such as the appropriate administration and
organization structure, 339 quality assurance that includes the program’s goals and objectives for
treatment,340 risk management and a system to report critical incidents (such as injuries or
deaths),341 and a diversion control plan. 342 Federal regulations also require a minimum amount
of annual drug screening tests for patients enrolled in OTPs, but does not condition a patient’s
continued enrollment or receipt of Controlled Substances with compliance. 343 Instead,
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SAMHSA guidance warns against decreasing or limiting doses of maintenance medication in
response to polysubstance abuse and instead suggests patient’s polysubstance abuse signals the
need for more intensive counseling and an increased dose of maintenance medication. 344
Licensing requirements, reporting, and inspection practices within each state vary based
on differing state law.345 Not all states require annual inspections, facilities may self-report
partial metrics (such as number of enrolled patients and retention in treatment) but not metrics
measuring polysubstance abuse and drug screen results, or impact of MAT on employment,
criminal activity, or adverse health outcomes.346 Accordingly, measures of “success” may
correspond to the number of enrolled patients, or the length of time in treatment without report of
crucial outcomes such as how many patients continue to abuse illicit substances and their quality
of life.347
The problem, according to Wickersham and Basey, is that accreditation status has
become a signifier of quality but lacks uniformity and transparency. 348 Wickersham & Basey’s
findings provide substantive research supporting troubling media stories 349 reporting how state
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health departments discovered OTPs with egregious compliance violations offering substandard
patient care despite high marks from CARF. 350 Further, some states do not require annual
inspections, which means no accounting of violations may exist, or alternatively, the public may
only discover violations after a legal complaint or publicized crime, such as patient death or
motor vehicle fatality. 351
C. Impact on Patient Care and Public Safety
The gaps in regulation, compliance, and enforcement translates to discrepancies in
provider quality, and creates a permissive regulatory environment for substandard medical care.
This impacts not only the patient’s life and well-being, but also public safety if patients are
impaired from prescribed medication, continue to engage in polysubstance abuse, and/or divert
the medication they receive into the illicit market. 352 Across the United States, patients who
sought comprehensive treatment for addiction filed lawsuits against OTPs, alleging claims
including negligence, medical malpractice, and fraud.353 Former patients assert the OTP

Treatment Center high marks); Duluth Methadone Clinic Cited for 22 New ‘Serious and Substantial Violations,
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provided failed to provide comprehensive counseling to address the social and psychological
factors underlying their addiction and instead solely prescribed methadone, which resulted in
serious physical and psychological adverse effects, fueling an addiction to another Controlled
Substance.354 Patients who are enrolled in treatment at an OTP may also overdose and die, 355 but
polysubstance abuse may undermine the ability to determine causality (whether the death was
caused solely or partially by the prescribed opioid), creating a high bar effectively precluding
legal recourse.356 Despite reports of patient harm in media 357 and several Plaintiffs
complaints,358 there is a dearth of case law. 359
Case law across several jurisdictions has addressed patient impairment when the patient’s
conduct impacts public safety and welfare. In multiple cases, patients who attended an OTP to
receive methadone continued to abuse other illicit substance while enrolled in MAT. 360 Patients
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may explicitly disclose their intention to continue to abuse multiple substances, 361 they may
demonstrate impairment (appearing disoriented, upset, red eyes, or nodding off),362 or may have
physical signs of continued substance abuse (new intravenous marks). 363
Many patients who visit an OTP drive extensive distances (over an hour) to attend the
clinic, receive their medication, then drive to work or home. 364 In Lingren v. Pinnacle Recovery
Services, patient Vanessa Brigan arrived early at Pinnacle Recovery Services to receive her daily
dose of methadone, “presented herself with fresh track marks, marijuana in her system, and
nodding off in the waiting room prior to receiving her methadone dose.” Pinnacle Recovery
Services provided Brigan the same daily dose and provided her a “take home” dose, despite
physical evidence she was injecting her take home doses while simultaneously abusing other
illicit substances. 365 Brigan drove away from the facility and stopped at a gas station to inject the
“take home dose.”366 Driving impaired under the influence of marijuana and two doses of
methadone, Brigan crossed the center line on the highway, striking another vehicle and killing
the driver.367 If OTPs do not share metrics of continued opioid abuse, polysubstance abuse, or
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track patient impairment, then it is foreseeable cases like Vanessa Brigan constitute only the tip
of the iceberg.
In similar cases such as Cheeks v. Dorsey, the court held OTPs have a duty to screen their
patients and adopt a policy for how to address when patients present with impairment at the
clinic.368 Without toxicology screening or an effective policy to monitor the patient, advise the
patient against driving, or arrange for alternate transportation, the OTP creates a risk that
unidentifiable third parties may become injured when the patient drives away from the clinic. 369
Some OTPs may have a drug screening policy in place and are acutely aware of patients’
ongoing abuse of multiple illicit substances because patients repeatedly test positive. 370 Yet if
the OTP adheres to SAMHSA’s guidance stating patient noncompliance should not prompt a
decrease or limitation in their maintenance medication and the OTP continues providing
maintenance medication to the patient, then the OTP likely faces liability if the patients leaves
the clinic impaired and causes injury to others. 371
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D. The Impact of a Flawed Treatment Model
This particular component of SAMHSA’s guidance constitutes a critical flaw, because it
both glosses over the significance of the patient’s continued drug abuse – a signal that MAT is
ineffective at addressing patient’s underlying addiction – and it places the public in harm’s way
from the conduct of the impaired patient. The effects of inadequate treatment impact the patient,
who continues to suffer addiction and adverse health effects that preclude recovery and
integration back to society. Presuming patients enrolled in MAT will continue to abuse illicit
substances and continuing to provide opioid agonist medications for patients to engage in selfharm is neither compassionate nor ethical. Such actions signal resignation to the patient, who
will suffer ongoing physical and psychological despair. In the cases describe above, patient
impairment reverberates to society when patients drive away from the clinic and cause
permanent and disabling injury to other motorists, 372 motor vehicle fatalities, 373 and crash into
unsuspecting pedestrians. 374 Patients also faces criminal charges with incarceration for injuries
and deaths that cannot be undone simply because they were impaired. 375 These outcomes
compel a re-examination of how MAT impacts both patients and how supporting the expansion
of MAT as a health policy strategy will magnify shortcomings of ineffective treatment and
societal harm.
CONCLUSION
Julie Eldred represents only one face of persons with OUD as a patient with a history of
addiction to opioids who became entangled in the criminal justice system from crimes she
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committed to fuel her addiction. The amicus briefs filed in support of Eldred and rhetoric set
forth by NIDA and SAMHSA portray a bleak prognosis for person suffering from addiction:
Eldred suffers from a chronic, relapsing brain disease over which she has little control and
enrolling her in MAT with a prescription for Suboxone constitutes the most effective form of
treatment. Yet extensive research in addiction science contradicts each of these statements,
showing narrow neurobiological models may undermine recovery, hinder appropriate medical
care that addresses polysubstance abuse, and confuse perceptions of legal culpability. The
current brain disease model of addiction constrains how we conceptualize addiction as a complex
series of choices that may or may not require different levels of treatment to address the social
and psychological issues underlying the patient’s addiction.
Importantly, discussing OUD requires precision to separate persons with addiction who
may require extensive supportive treatment from persons with physiological dependence
attempting to discontinue prescribed medication but facing severe physical and psychological
withdrawal symptoms. Research on MAT demonstrates an extensive profile of physical risks
that negatively impact quality of life; research demonstrating neurological damage from opioid
agonist maintenance treatment and risks from opioid antagonist treatment; and forceful financial
entanglements promoting pharmacological solutions. Long term MAT for persons with
iatrogenic opioid dependence is not only inappropriate, but as Fischer and colleagues suggested
will likely create a new epidemic of impaired persons dependent or addicted to a new controlled
substance.
For persons who do suffer from addiction, available research casts doubt on the efficacy
of MAT because the majority of patients continue polysubstance abuse, some may develop
dependence or addiction to the prescribed maintenance medication itself, and patients may
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continue to struggle with activities of daily life undermining claims of reintegration and
recovery. As OTPs expand, patterns from media reports, lawsuits, and case law suggest
discrepancies in provider quality, portray numerous facilities as merely providing another opioid
without providing comprehensive treatment, and demonstrate insufficient attention to addressing
patients’ extensive medical, psychological, and social needs. This model not only fails to as a
policy for promoting compassionate and evidence-based care for persons struggling with
addiction but places the public at risk of more crime and injury arising from patients’
maladaptive actions arising from impaired decision-making.
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